COVID-19 Clinical Trials in Phoenix

Showing 61-75 of 75 trials

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

NCT04414618

This proof of concept study will take place in the US and other countries in approximately 15 clinical sites and will enroll about 40 hospitalized patients diagnosed with COVID-19 infection who have developed pneumonia and require supplemental oxygen. 20 patients will receive opaganib in addition to standard of care twice each day for 14 days. 20 will receive matching placebo in addition to standard of care unless the patient has been discharged from the hospital without requiring supplemental oxygen, in which case study drug will only be administered for 10 days. All participants will be followed up for 4 weeks after their last dose of study drug.

Coronavirus Infections

RedHill Biopharma Limited42 participantsStarted Jul 2020

Scottsdale, Arizona, United States • Miami, Florida, United States • Detroit, Michigan, United States +6 more locations

TERMINATEDPHASE311 miles

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

NCT04377620

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib in the treatment of participants with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS) who require mechanical ventilation.

COVID-19

Incyte Corporation211 participantsStarted May 2020

Scottsdale, Arizona, United States • San Diego, California, United States • Washington D.C., District of Columbia, United States +33 more locations

A Study of Opaganib in Coronavirus Disease 2019 Pneumonia

Assessment of Efficacy and Safety of Ruxolitinib in Participants With COVID-19-Associated ARDS Who Require Mechanical Ventilation (RUXCOVID-DEVENT)

COVID-19 Trials in Other Cities

Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)

Outcomes Related to COVID-19 Treated With Hydroxychloroquine Among In-patients With Symptomatic Disease

Study of Multiple Candidate Agents for the Treatment of COVID-19 in Hospitalized Patients

COVID-19 Progression in End-Stage Kidney Disease

A Study to Evaluate the Safety and Efficacy of Tocilizumab in Patients With Severe COVID-19 Pneumonia

NA-831, Atazanavir and Dexamethasone Combination Therapy for the Treatment of COVID-19 Infection

A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19

Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood

A Phase 3 Randomized Double Blind Efficacy and Safety Study of Oral Polio Vaccine and NA-831 for Covid-19

Study to Evaluate a Single Dose of STI-2020 (COVI-AMG™) in Adults With Mild COVID-19 Symptoms

Point-of-care Lung Ultrasound (POCUS)-Integrated Study of Admitted Patients With COVID-19

A Study of Immune Responses to the Virus That Causes COVID-19

Treatment for COVID-19 in High-Risk Adult Outpatients

Other Conditions in Phoenix